Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz

HIV Clinical Trials

Volumn 12, Issue 2, 2011, Pages 61-70

  McColl, Damian J ^a   Margot, Nicolas ^a   Chen, Shan Shan ^a   Harris, Jeanette ^a   Borroto Esoda, Katyna ^a   Miller, Michael D ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

3TC; antiretroviral drug resistance; emtricitabine; FTC; HIV 1 nucleoside reverse transcriptase inhibitors; human immunodeficiency virus type 1; lamivudine; M184V I

Indexed keywords

DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; STAVUDINE; TENOFOVIR DISOPROXIL; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; DOUBLE BLIND PROCEDURE; DRUG RESISTANCE; FEMALE; FISHER EXACT TEST; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MUTATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; VIROLOGY; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LAMIVUDINE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 79955061504     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1202-61     Document Type: Article

References (39)

1. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009;33(4):307-320.
2. Hui CK, Zhang HY, Bowden S, et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol. 2008;48(5):714-720.
3. Nguyen MH, Keeffe EB. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepatol. 2009;16(3):149-155.
4. Piliero PJ. Pharmacokinetic properties of nucleoside/ nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2004;37(Suppl 1):S2-S12. (Pubitemid 39166639)
5. Back DJ, Burger DM, Flexner CW, Gerber JG. The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing.J Acquir Immune Defic Syndr. 2005;39(Suppl 1):S1-23.
6. Bartlett JA, Chen SS, Quinn JB. Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview.HIV Clin Trials. 2007;8(4):221-226. (Pubitemid 47327459)
7. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA.2010;304(3):321-333.
8. Schinazi RF. Assessment of the relative potency of emtricitabine and lamivudine. J Acquir Immune Defic Syndr Human Retrovirol. 2003;34(2):243-245.
9. Feng JY, Anderson KS. Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase. Biochemistry. 1999;38(1):55-63. (Pubitemid 29035670)
10. Rousseau FS, Kahn JO, Thompson M, et al. Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J Antimicrob Chemother.2001;48(4):507-513. (Pubitemid 33040691)
11. Rousseau FS, Wakeford C, Mommeja-Marin H, et al.Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis. 2003;188(11): 1652-1658. (Pubitemid 38010675)
12. Moore KHP, Barrett JE, Shaw S, et al. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS.1999;13(16):2239-2250. (Pubitemid 29531443)
13. Wang LH, Begley J, St. Claire RL, Harris J, Wakeford C, Rousseau FS. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Human Retroviruses. 2004;20(11):1173-1182. (Pubitemid 39557868)
14. Boucher CA, Cammack N, Schipper P, et al. High-level resistance to (-) enantiomeric 2'-deoxy-2'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother.1993;37(10):2231-2234. (Pubitemid 23298217)
15. Margot NA, Waters JM, Miller MD. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrob Agents Chemother.2006;50(12):4087-4095. (Pubitemid 44865153)
16. Gao H-Q, Boyer PL, Sarafianos SG, Arnold E, Hughes SH.The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. J Molecular Biol. 2000;300(2):403-418.
17. McColl DJ, Chappey C, Parkin NT, Miler MD. Prevalence, genotypic assiciations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database. Antivir Ther. 2008;13:189-197. (Pubitemid 351535370)
18. Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA.2004;292(2):180-190. (Pubitemid 38917995)
19. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.JAMA. 2004;292(2):191-201. (Pubitemid 38917996)
20. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. New Engl J Med. 2006;354(3): 251-260. (Pubitemid 43113030)
21. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Antiretroviral Drugs Using Plasma HIV RNA Measurements - Clinical Considerations for Accelerated and Traditional Approval.Rockville, MD: Author; October 2002.
22. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother.2000;44:920-928. (Pubitemid 30165271)
23. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med. 2005;13(4):125-131.
24. Borroto-Esoda K, Waters JM, Bae AS, et al. Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz.AIDS Res Hum Retroviruses. 2007;23(8):988-995. (Pubitemid 47492339)
25. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis. 2008;197(6):867-870. (Pubitemid 351417010)
26. Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naive subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in Study GS-01-934. J Acquir Immune Defic Syndr.2009;52(2):209-221.
27. Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med.2006;3(9):e356.
28. Lima VD, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS. 2008;22(17):2371-2380.
29. Svicher V, Alteri C, Artese A, et al. Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. J Acquir Immune Defic Syndr. 2010;55(3):336-344.
30. White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother. 2002;46(11):3437-3446. (Pubitemid 35192909)
31. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004;189(5):837-846. (Pubitemid 38328185)
32. Maserati R, De Silvestri A, Uglietti A, et al. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. AIDS.2010;24:1013-1018.
33. Johnson MA, Gathe JC Jr, Podzamczer D, et al.A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr. 2006;42(2): 153-160. (Pubitemid 44454808)
34. Molina JM, Andrade-Villanueva J, Echevarria J, et al.Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV- 1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372(9639):646-655.
35. Elion R, Cohen C, Ward D, et al. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1- infected, antiretroviral-naive patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily. HIV Clin Trials. 2008;9(4):213-224.
36. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS.2008;22(12):1389-1397.
37. Walmsley S, Ruxrungtham K, Slim J, Ward D, Larson P, Raffi F. The Gemini Study: Saquinavir/r (SQV/r) vs lopinavir/r (LPV/r) plus emtricitabine/tenofovir (FTC/TDF) as initial therapy in HIV-1 infected patients [oral presentation PS1/4]. Paper presented at: 11th European AIDS Conference (EACS); October 24-27, 2007; Madrid, Spain.
38. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23:1547-1556.
39. Frankel FA, Invernizzi CF, Oliveira M, Wainberg MA. Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations. AIDS.2007;21(6):665-675. (Pubitemid 46568623)